文献速递心力衰竭与心肌病

Mavacamten治疗症状性非梗阻性肥厚型心肌病的评估

Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy.
PubMed 文献 · J Am Coll Cardiol · 2020-01-01

结果显示Mavacamten总体耐受良好,且显著降低NT-proBNP和cTnI,提示心肌壁应力改善。

要点

  • Mavacamten在症状性nHCM患者中总体耐受良好,严重不良事件发生率低于安慰剂组。
  • Mavacamten显著降低NT-proBNP(几何均值下降53% vs 1%)和cTnI(下降34% vs 升高4%)。
  • 5例接受Mavacamten的患者出现可逆性LVEF降低至≤45%。

核心结论

  • Mavacamten在多数症状性nHCM受试者中耐受良好,且与NT-proBNP和cTnI显著降低相关,提示心肌壁应力改善。

研究设计与样本

  • 参与者按1:1:1随机接受药代动力学调整剂量的Mavacamten(目标血浆浓度200或500 ng/ml)或安慰剂治疗16周,随后8周洗脱。
  • 初始剂量为每日5 mg,第6周进行一次剂量滴定。

主要发现

  • 严重不良事件在接受Mavacamten的参与者中发生率为10%,在安慰剂组为21%。
  • 5例接受Mavacamten的参与者出现可逆性LVEF降低至≤45%。
  • 汇总Mavacamten组NT-proBNP几何均值下降53%,安慰剂组下降1%,几何均值差异分别为-435 pg/ml和-6 pg/ml(p=0.0005)。
  • 汇总Mavacamten组cTnI几何均值下降34%,安慰剂组升高4%,几何均值差异分别为-0.008 ng/ml和0.001 ng/ml(p=0.009)。

临床怎么用

  • Mavacamten在此II期研究中显示出改善心肌壁应力的潜力,支持未来以LVEF等临床参数指导剂量的研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with nonobstructive hypertrophic cardiomyopathy (nHCM) often experience a high burden of symptoms; however, there are no proven pharmacological therapies. By altering the contractile mechanics of the cardiomyocyte, myosin inhibitors have the potential to modify pathophysiology and improve symptoms associated with HCM. OBJECTIVES: MAVERICK-HCM (Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy) explored the safety and efficacy of mavacamten, a first-in-class reversible inhibitor of cardiac-specific myosin, in nHCM. METHODS: The MAVERICK-HCM trial was a multicenter, double-blind, placebo-controlled, dose-ranging phase II study in adults with symptomatic nHCM (New York Heart Association functional class II/III), left ventricular ejection fraction (LVEF) ≥55%, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) ≥300 pg/ml. Participants were randomized 1:1:1 to mavacamten at a pharmacokinetic-adjusted dose (targeting plasma levels of 200 or 500 ng/ml), or placebo for 16 weeks, followed by an 8-week washout. Initial dose was 5 mg daily with 1 dose titration at week 6. RESULTS: Fifty-nine participants were randomized (19, 21, 19 patients to 200 ng/ml, 500 ng/ml, placebo, respectively). Their mean age was 54 years, and 58% were women. Serious adverse events occurred in 10% of participants on mavacamten and in 21% participants on placebo. Five participants on mavacamten had reversible reduction in LVEF ≤45%. NT-proBNP geometric mean decreased by 53% in the pooled mavacamten group versus 1% in the placebo group, with geometric mean differences of -435 and -6 pg/ml, respectively (p = 0.0005). Cardiac troponin I (cTnI) geometric mean decreased by 34% in the pooled mavacamten group versus a 4% increase in the placebo group, with geometric mean differences of -0.008 and 0.001 ng/ml, respectively (p = 0.009). CONCLUSIONS: Mavacamten, a novel myosin inhibitor, was well tolerated in most subjects with symptomatic nHCM. Furthermore, treatment was associated with a significant reduction in NT-proBNP and cTnI, suggesting improvement in myocardial wall stress. These results set the stage for future studies of mavacamten in this patient population using clinical parameters, including LVEF, to guide dosing. (A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy [MAVERICK-HCM]; NCT03442764).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Ho CY, Mealiffe ME, Bach RG, et al. Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2020. PMID: 32466879. doi:10.1016/j.jacc.2020.03.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。